NHF Statement on Approval of the Pfizer-BioNTech Vaccine for Children Ages 5-11

COVID-19 vaccine for children ages 5-11 receives final approval.

“NHF applauds the CDC’s recommendation of the Pfizer-BioNTech COVID-19 vaccine for children 5 to 11 years of age. Evidence-based studies have long shown that children benefit from many safe and effective vaccines already – and now, with the COVID-19 vaccine, children and families can be more protected than ever before. For children with chronic conditions like hemophilia or other inheritable blood disorders, a COVID-19 vaccine is imperative to promoting their health and safety in these challenging times.” – Dr. Leonard A. Valentino, Pediatric Hematologist and NHF CEO/President

Source: National Hemophilia Foundation

Back to all News